IntroductionEwing’s sarcoma (ES) is a highly malignant tumour of bone and/or soft tissue, which is commonly observed during adolescence and young adulthood, and exhibits a distinct propensity for aggressive behaviour.1 It accounts for approximately 15% of all bone malignancies and primarily affects the metaphyseal region of long bones, representing around 80% of reported cases.2,3Furthermore, at the time of diagnosis, around 20% of patients have metastatic spread to distant sites.4Ewing’s sarcoma is typically found in the axial and appendicular skeleton, but rarely occurs in the foot, particularly in the talus.5 It has been reported that the occurrence of ES has not been linked to hereditary or congenital syndromes, environmental factors, or established risk factors. In approximately 90% of cases, the neoplastic cells of Ewing’s sarcoma family tumours (ESFT) show a characteristic translocation t(11;22)(q24;q12), while the remaining 10% display a variant translocation, specifically t(21;12)(22;12).6 Prognostic indicators that result in poor outcomes include tumour size of 8 cm or larger, primary tumour located in the pelvic region, presence of metastases, and age exceeding 15 years at the time of diagnosis.7